Status:
COMPLETED
Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil
Lead Sponsor:
University of Zurich
Conditions:
Hypertension, Pulmonary
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To study the effect of acute normobaric hypoxia during exercise in patients with pulmonary hypertension with/without Sildenafil
Eligibility Criteria
Inclusion
- Informed consent as documented by signature (Appendix Informed Consent Form)
- PH class I (PAH) or IV (CTEPH) diagnosed according to guidelines: mean pulmonary artery pressure \>20 mmHg, pulmonary vascular resistance ≥3 wood units, pulmonary arterial wedge pressure ≤15 mmHg during baseline measures at the diagnostic right-heart catheterization
Exclusion
- resting partial pressure of oxygen \<8 kilopascal at Zürich altitude on ambient air
- exposure to an altitude \>1000 m for ≥3 nights during the last 2 weeks before the study
- inability to follow the procedures of the study
- patients who take nitrates
- other clinically significant concomitant end-stage disease (e.g., renal failure, hepatic dysfunction)
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2023
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04697862
Start Date
February 1 2021
End Date
May 31 2023
Last Update
June 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UniversityHospital Zurich, Department of Pulmonology
Zurich, Switzerland, 8091